Two Million DBS Samples Received, Analyzed, and Reported
In December 2021, we reached our first million Dried Blood Spot (DBS) samples. this December 2024, just three years later, we achieved another million, bringing our total to 2 million DBS samples. In 2023, we received approximately 330,000 samples, and in 2024, 436,000 samples, marking a 33% increase within a year. We anticipate similar growth in the coming years and estimate reaching a total of 3 million samples by 2026 and 1 million samples per year by 2028.
Dried blood spots (DBS) biomarker analysis is a powerful technique for assessing health and disease by collecting and analyzing small volumes of blood on absorbent cards. This method offers numerous advantages, including ease of sample collection, transport, and storage, making it particularly useful in remote or resource-limited settings. DBS analysis allows for the measurement of various biomarkers, including proteins, metabolites, and genetic material, enabling the monitoring of diseases such as diabetes, cardiovascular disorders, and infectious diseases. The technique is increasingly being utilized in clinical research and diagnostics, facilitating early detection and personalized medicine through efficient and cost-effective approaches.
Pioneering DBS Analysis
Vitas AS is a pioneering company specializing in DBS analysis, revolutionizing biomarker testing. By utilizing this innovative method, Vitas facilitates efficient sample collection and transport, enabling precise disease monitoring and early detection. Our advancements position us as leaders in the field of diagnostics and personalized medicine.
Advanced Instrumentation and Techniques
Our excellence in DBS handling and analysis is reflected in our advanced instrumentation and techniques. We utilize Hamilton Robotics for efficient sample processing alongside various analytical methods, including UPLC, GC, LC-MS/MS, ICP-MS, and GC-FID. This multifaceted approach enables us to accurately quantify various biomarkers and enhance the reliability of our results.
Expanding Instrument Park
Our instrument park is continuously expanding to meet the growing demands of our research and diagnostic needs. Currently, we operate over 35 state-of-the-art instruments, each selected for its ability to deliver precise and reproducible measurements. This extensive setup boosts our analytical capabilities and supports the development of new assays and methodologies. By integrating cutting-edge technology and automation, we aim to streamline workflows, improve throughput, and provide high-quality diagnostic solutions for our clients.
Continuous Development
Vitas is committed to the continuous development of new assays for DBS, enhancing diagnostic capabilities and biomarker analysis. This ongoing innovation allows for improved detection of various diseases, supporting personalized medicine. By expanding our assay portfolio, we ensure reliable, efficient, and accessible testing for diverse health conditions.
New Assays Developed in 2024
In 2024, several new assays have been developed. After years of attempts, we have successfully created DBS assays for ApoB100 and ApoA1, which serve as superior substitutes for LDL and HDL, respectively. These biomarkers offer direct insights into particle numbers, enhance cardiovascular risk assessment, and reduce the influence of triglyceride levels. Together with other biomarkers like Lp(a), NTproBNP, creatinine, HbA1c, hsCRP, and total cholesterol, these new assays will be used in population screenings to map CVD risk.
Get in Touch
Please see our list of DBS methods below and browse our publications on this topic. If you have projects or services that could benefit from DBS as a collection platform and would like to discuss a collaboration, please contact Thomas E. Gundersen at teg@vitas.no.